MEDIA ALERT: For Immediate Release
April 28, 2026

Parexel Statement on U.S. Food and Drug Administration Announcement "FDA Announces Major Steps to Implement Real-Time Clinical Trials: *Agency unveils real-time trial proofs-of-concept and upcoming pilot program*"

RALEIGH, N.C., April 28, 2026 – Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today provided a statement supporting the U.S. Food and Drug Administration (FDA) announcement around Real-Time Clinical Trials (RTCT).

Parexel believes the RTCT program marks a landmark shift in how clinical evidence is generated and evaluated. The initiative is designed to let sponsors and regulators review data in parallel, cutting time lags, accelerating development, and improving the experience for sites and patients. Parexel welcomes this progress as it clearly aligns with our focus on driving speed, predictability, and data advantage. This is the direction we have been building toward and validates our multi-year investment in AI-driven clinical infrastructure and innovation. It also underscores our partnership with Paradigm Health, announced in September 2025.

"We have invested in AI, built deep regulatory relationships, and can support continuous data flows, meaning we are absolutely ready and excited to partner with FDA and sponsors to scale this model," said Peyton Howell, CEO of Parexel. "We are already working with our large pharma partners on in-progress studies and to design pilots for this program. And, access for biotech sponsors will be critical. Parexel Biotech is a leader that brings experience and agility to move biotech studies forward with speed, predictability and efficiency."

Parexel is already moving forward on the RTCT initiative with the regulatory expertise, AI infrastructure, global site network, and partnerships to execute at scale today. Parexel has worked on >70 designated "Breakthrough" and accelerated programs with FDA. Our AI partnerships are delivering a 50% reduction in regulatory filing submission prep time, AI-automated SDTM transformation, and an end-to-end clinical data platform running at scale.

Additional experts at Parexel available for media interviews on this topic include Rob Goodwin, COO; Paul Bridges, President of Consulting and Regulatory; and Tala Fakhouri, Chief AI & Regulatory Strategy Officer among others.

Media
Heather Zoumas-Lubeski
+1 984 218 5539
Heather.Zoumas-Lubeski@parexel.com

Danaka Williams
+1 984 298 4207
Danaka.Williams@parexel.com